Onesource Specialty Pharma is currently trading at Rs. 1572.20, up by 2.55 points or 0.16% from its previous closing of Rs. 1569.65 on the BSE.
The scrip opened at Rs. 1569.55 and has touched a high and low of Rs. 1600.00 and Rs. 1535.40 respectively. So far 79114 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1924.00 on 03-Nov-2025 and a 52 week low of Rs. 1075.00 on 30-Jan-2026.
Last one week high and low of the scrip stood at Rs. 1642.60 and Rs. 1,325.70 respectively. The current market cap of the company is Rs. 18277.34 crore.
The promoters holding in the company stood at 30.47%, while Institutions and Non-Institutions held 43.65% and 25.86% respectively.
Onesource Specialty Pharma has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a 'Voluntary Action Indicated' (VAI) classification. The report follows an inspection of the facility conducted from June 22 to June 30, 2026.
The development adds to the company’s regulatory track record as it continues to build a differentiated, globally competitive CDMO platform spanning four key modalities - drug-device combination, biologics, sterile injectables and soft gelatin capsules.
OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.
